ABL Bio Inc. (KOSDAQ:298380)

ABL Bio Statistics

Total Valuation

ABL Bio has a market cap or net worth of KRW 9.56 trillion. The enterprise value is 9.47 trillion.

Market Cap	9.56T
Enterprise Value	9.47T

Important Dates

The last earnings date was Monday, November 10, 2025.

Earnings Date	Nov 10, 2025
Ex-Dividend Date	n/a

Share Statistics

ABL Bio has 55.13 million shares outstanding. The number of shares has increased by 3.78% in one year.

Current Share Class	55.13M
Shares Outstanding	55.13M
Shares Change (YoY)	+3.78%
Shares Change (QoQ)	+11.14%
Owned by Insiders (%)	26.15%
Owned by Institutions (%)	15.15%
Float	40.71M

Valuation Ratios

PE Ratio	n/a
Forward PE	656.20
PS Ratio	108.09
PB Ratio	52.46
P/TBV Ratio	53.29
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-330.77
EV / Sales	107.14
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-175.37

Financial Position

The company has a current ratio of 2.53, with a Debt / Equity ratio of 0.24.

Current Ratio	2.53
Quick Ratio	2.49
Debt / Equity	0.24
Debt / EBITDA	n/a
Debt / FCF	-0.80
Interest Coverage	-49.05

Financial Efficiency

Return on equity (ROE) is -15.80% and return on invested capital (ROIC) is -8.28%.

Return on Equity (ROE)	-15.80%
Return on Assets (ROA)	-7.78%
Return on Invested Capital (ROIC)	-8.28%
Return on Capital Employed (ROCE)	-16.26%
Revenue Per Employee	867.02M
Profits Per Employee	-280.83M
Employee Count	102
Asset Turnover	0.37
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +522.62% in the last 52 weeks. The beta is 0.74, so ABL Bio's price volatility has been lower than the market average.

Beta (5Y)	0.74
52-Week Price Change	+522.62%
50-Day Moving Average	112,262.00
200-Day Moving Average	75,599.00
Relative Strength Index (RSI)	71.34
Average Volume (20 Days)	1,709,459

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ABL Bio had revenue of KRW 88.44 billion and -28.65 billion in losses. Loss per share was -575.91.

Revenue	88.44B
Gross Profit	88.38B
Operating Income	-29.84B
Pretax Income	-28.67B
Net Income	-28.65B
EBITDA	-26.75B
EBIT	-29.84B
Loss Per Share	-575.91

Balance Sheet

The company has 127.20 billion in cash and 43.48 billion in debt, giving a net cash position of 83.73 billion or 1,518.84 per share.

Cash & Cash Equivalents	127.20B
Total Debt	43.48B
Net Cash	83.73B
Net Cash Per Share	1,518.84
Equity (Book Value)	182.22B
Book Value Per Share	3,384.69
Working Capital	78.55B

Cash Flow

In the last 12 months, operating cash flow was -33.19 billion and capital expenditures -20.84 billion, giving a free cash flow of -54.03 billion.

Operating Cash Flow	-33.19B
Capital Expenditures	-20.84B
Free Cash Flow	-54.03B
FCF Per Share	-980.12

Margins

Gross margin is 99.93%, with operating and profit margins of -33.74% and -32.39%.

Gross Margin	99.93%
Operating Margin	-33.74%
Pretax Margin	-32.42%
Profit Margin	-32.39%
EBITDA Margin	-30.25%
EBIT Margin	-33.74%
FCF Margin	n/a

Dividends & Yields

ABL Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.78%
Shareholder Yield	-3.78%
Earnings Yield	-0.30%
FCF Yield	-0.57%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ABL Bio has an Altman Z-Score of 29.65 and a Piotroski F-Score of 2.

Altman Z-Score	29.65
Piotroski F-Score	2